Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents

doi:10.3760/cma.j.issn.1673-422X.2016.08.015

Abstract

Abstract: The development of primary or acquired taxane resistance inevitably becomes to be the main problem. Ixabepilone is effective in metastatic breast cancer (MBC) patients including those heavily pretreated or resistant to taxanes. Eribulin has been used for the treatment of MBC patients who have received at least two prior chemotherapy regimens. New microtubuletargeting agents are promising to be effective options for patients progressing after standard taxanecontaining chemotherapy.

Key words: Breast neoplasms, Taxoids, Drug resistance, Microtubules

Huang Yuan, Liu Danli, Wang Xiaojia. Taxane resistance in metastatic breast cancer and novel microtubuletargeting agents[J]. Journal of International Oncology, 2016, 43(8): 622-624.

References

［1］ Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy［J］. Cancers (Basel), 2015, 7(4): 2360-2371. DOI: 10.3390/cancers7040897. ［2］吴静, 杨睿, 刘树业. 肿瘤多药耐药的产生机制及逆转策略［J］. 国际肿瘤学杂志, 2013, 40(12): 889-892. DOI: 10.3760/cma.j.issn.1673-422X.2013.12.003. ［3］ Karki R, Mariani M, Andreoli M, et al. βⅢTubulin: biomarker of taxane resistance or drug target?［J］. Expert Opin Ther Targets, 2013, 17(4): 461-472. ［4］ Kavallaris M. Microtubules and resistance to tubulinbinding agents［J］. Nat Rev Cancer, 2010, 10(3): 194-204. DOI: 10.1038/nrc2803. ［5］ Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities［J］. Nat Prod Rep, 2014, 31(3): 335-355. DOI: 10.1039/c3np70092e. ［6］ Nobili S, Landini I, Mazzei T, et al. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression［J］. Med Res Rev, 2012, 32(6): 1220-1262. DOI: 10.1002/med.20239. ［7］ Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone［J］. Cancer Chemother Pharmacol, 2009, 63(2): 201-212. DOI: 10.1007/s00280-008-0727-5. ［8］ Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase Ⅱ study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine［J］. J Clin Oncol, 2007, 25(23): 3407-3414. DOI: 10.1200/JCO.2006.09.3849. ［9］ Thomas E, Tabernero J, Fornier M, et al. Phase Ⅱ clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer［J］. J Clin Oncol, 2007, 25(23): 3399-3406. DOI: 10.1200/JCO.2006.08.9102. ［10］ Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase Ⅲ study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes［J］. Breast Cancer Res Treat, 2010, 122(2): 409-418. DOI: 10.1007/s10549-010-0901-4. ［11］ Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase Ⅲ trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2010, 28(20): 3256-3263. DOI: 10.1200/JCO.2009.24.4244. ［12］ Roché H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase Ⅲstudies［J］. Breast Cancer Res Treat, 2011, 125(3): 755-765. DOI: 10.1007/s10549-010-1251-y. ［13］ Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents［J］. Clin Breast Cancer, 2010, 10(1): 64-73. DOI: 10.3816/CBC.2010.n.009. ［14］ Chuang E, Wiener N, Christos P, et al. Phase Ⅰtrial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary［J］. Ann Oncol, 2010, 21(10): 2075-2080. ［15］ Moulder S, Li H, Wang M, et al. A phaseⅡ trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2positive metastatic breast cancer: an eastern cooperative oncology group trial［J］. Breast Cancer Res Treat, 2010, 119(3): 663-671. DOI: 10.1007/s10549-009-0658-9. ［16］ Vahdat LT, Pruitt B, Fabian CJ, et al. Phase Ⅱ study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2009, 27(18): 2954-2961. DOI: 10.1200/JCO.2008.17.7618. ［17］ Cortes J, Vahdat L, Blum JL, et al. Phase Ⅱstudy of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine［J］. J Clin Oncol, 2010, 28(25): 3922-3928. DOI: 10.1200/JCO.2009.25.8467. ［18］ Cortes J, O′shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician′s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study［J］. Lancet, 2011, 377(9769): 914-923. DOI: 10.1016/S0140-6736(11)60070-6. ［19］ Kaufman PA, Awada A, Twelves C, et al. Phase Ⅲ open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2015, 33(6): 594-601. DOI: 10.1200/JCO.2013.52.4892.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[12]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.